These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8549387)

  • 1. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of levofloxacin in the treatment of respiratory tract infection.
    Shah PM
    J Chemother; 2000 Oct; 12 Suppl 4():27-31. PubMed ID: 11131957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 4. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
    Sato A; Ogawa H; Iwata M; Ono T; Yasuda K; Nagayama M; Shirai T; Shirai M; Ida M; Suda T
    Drugs; 1995; 49 Suppl 2():428-9. PubMed ID: 8549388
    [No Abstract]   [Full Text] [Related]  

  • 7. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
    Blasi F
    J Chemother; 2004 Apr; 16 Suppl 2():11-4. PubMed ID: 15255556
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 10. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 11. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
    Harazim H; Wimmer J; Mittermayer HP
    Drugs; 1987; 34 Suppl 1():71-3. PubMed ID: 3481331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
    McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
    Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy and safety of levofloxacin in low respiratory tract infection].
    Zubkov MN
    Antibiot Khimioter; 2004; 49(5):31-7. PubMed ID: 15573900
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
    Kawahara S; Watanabe Y; Matsuka Y; Sato T; Takahashi K
    Drugs; 1995; 49 Suppl 2():414-5. PubMed ID: 8549382
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of lower respiratory tract infections in the elderly].
    Komarova VP; Belousov IuB; Sokolov AV; Tishchenkova IF; Efremenkova OV
    Antibiot Khimioter; 1997; 42(12):19-24. PubMed ID: 9480649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Observational study investigating the use of levofloxacin in ICU patients].
    Alvarez-Lerma F; Palomar M; Olaechea P; León C; Sánchez M; Bermejo B;
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):220-6. PubMed ID: 15056438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
    Yanagihara K; Tomono K; Sawai T; Kuroki M; Kaneko Y; Ohno H; Higashiyama Y; Miyazaki Y; Hirakata Y; Maesaki S; Kadota J; Tashiro T; Kohno S
    J Antimicrob Chemother; 2000 Jul; 46(1):69-72. PubMed ID: 10882691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 20. Additive effect of continuous low dose ofloxacin on erythromycin therapy for sinobronchial syndrome.
    Fujimura M; Ishiura Y; Saito M; Shibata K; Nomura M; Nakatsumi Y; Matsuda T
    Drugs; 1995; 49 Suppl 2():409-11. PubMed ID: 8549380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.